Portal Hypertension

  1. Krowka MJ. Hepatopulmonary Syndrome and Portopulmonary Hypertension. Curr Treat Options Cardiovasc Med 2002;4(3):267-273.
  2. Naeije R. Hepatopulmonary syndrome and portopulmonary hypertension. Swiss Med Wkly 2003;133(11-12):163-9.
  3. Nicod LP. Pulmonary hypertension. Swiss Med Wkly 2003;133(7-8):103-10.
  4. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003;361(9368):1533-44.
  5. Kuo PC, Schroeder RA, Vagelos RH, et al. Volume-mediated pulmonary responses in liver transplant candidates. Clin Transplant. 1996;10(6 Pt 1):521-7.
  6. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J. 2004;24(5):861-80.
  7. Martinez GP, Barbera JA, Visa J, et al. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol. 2001;34(5):651-7.
  8. Lange PA, Stoller JK. The hepatopulmonary syndrome. Ann Intern Med. 1995;122(7):521-9.
  9. Herve P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J. 1998;11(5):1153-66.
  10. Krowka MJ, Porayko MK, Plevak DJ, et al. Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Mayo Clin Proc. 1997;72(1):44-53.
  11. Krowka MJ. Hepatopulmonary syndrome versus portopulmonary hypertension: distinctions and dilemmas. Hepatology. 1997;25(5):1282-4.
  12. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991;17(2):492-8.
  13. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983;127(4):437-41.
  14. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991;100(2):520-8.
  15. Yang YY, Lin HC, Lee WC, et al. Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations. J Gastroenterol 2001;36(3):181-6.
  16. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997;3(5):494-500.
  17. Castro M, Krowka MJ, Schroeder DR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996;71(6):543-51.
  18. Taura P, Garcia-Valdecasas JC, Beltran J, et al. Moderate primary pulmonary hypertension in patients undergoing liver transplantation. Anesth Analg 1996;83(4):675-80.
  19. Starkel P, Vera A, Gunson B, Mutimer D. Outcome of liver transplantation for patients with pulmonary hypertension. Liver Transpl 2002;8(4):382-8.
  20. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6(4):443-50.
  21. Ramsay MA. Perioperative mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl. 2000;6(4):451-2.
  22. De Wolf AM, Scott VL, Gasior T, Kang Y. Pulmonary hypertension and liver transplantation. Anesthesiology 1993;78(1):213-4.
  23. Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl. 2004;10(2):174-82.
  24. Plotkin JS, Kuo PC, Rubin LJ, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998;65(4):457-9.
  25. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30(3):641-8.
  26. Tan HP, Markowitz JS, Montgomery RA, et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transpl 2001;7(8):745-9.
  27. Ramsay MA, Spikes C, East CA, et al. The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol. Anesthesiology 1999;90(1):299-301.
  28. Mair P, Kaehler CH, Pomaroli A, Schwarz B, Vogel W, Margreiter R. Orthotopic liver transplantation in a patient with severe portopulmonary hypertension. Acta Anaesthesiol Scand 2001;45(4):513-8.
  29. McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med. 1999;130(9):740-3.
  30. Benza RL, Thallaj JA, Rayburn BK, Foley BA, Bourge RC, Roscigno R. Safety and efficacy of trepostinil in cirrhosis-related pulmonary arterial hypertension. Presented at the 54th Annual meeting of the American Association for the Study of Liver Diseases. Boston 2003.
  31. Ramsay MA. Liver Transplant Considerations and Outcome for Portopulmonary Hypertension Patient. Advances in Pulmonary Hypertension 2004 Summer.
  32. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896-903.
  33. Barth F, Gerber PJ, Reichen J, Dufour JF, Nicod LP. Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency. Eur J Gastroenterol Hepatol 2006;18(10):1117-9.
  34. Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25(3):502-8.